EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Case Report: Pembrolizumab-associated airway-predominant relapsing polychondritis with longitudinal CD8+ T-cell activation and bronchial stenting

Can Xia, Jie Chen, Xia Fang, Changwen Deng, Xiaoping Zhu, Shuang Ye, Runci Wang

Frontiers in Immunology · 2026

DOI: 10.3389/fimmu.2026.1999620 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Immunology, 2026. Verfasst von Can Xia und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Polychondritis, Relapsing, CD8-Positive T-Lymphocytes, Lymphocyte Activation. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) can trigger autoimmune and autoinflammatory toxicities through disruption of peripheral immune tolerance. Relapsing polychondritis (RP) after programmed cell death protein 1 (PD-1) blockade is rare and are described mainly in individual reports. We report a 66-year-old man who developed severe airway-predominant RP after 10 cycles of pembrolizumab for lung adenocarcinoma. Chest CT showed new diffuse tracheal and bilateral bronchial wall thickening and calcification, with severe obstructive ventilatory impairment and systemic inflammation. Exploratory serial peripheral-blood immunophenotyping demonstrated increased proportions of CD38+ and HLA-DR+ cells among circulating CD8+ T cells early in the disease course. Serial measurements showed lower activated CD8+ T-cell proportions during immunosuppressive treatment, in parallel with partial stabilization of respiratory symptoms, pulmonary function and imaging. The patient received sequential glucocorticoids, tofacitinib, methotrexate, abatacept and tocilizumab. Despite partial inflammatory control, subsequent pulmonary infection with severe coughing was followed by pneumomediastinum and progressive structural airway compromise requiring bilateral main-bronchial stenting. One year after stenting, the stents remained in situ with no obvious luminal stenosis and pulmonary function remained stable. This case extends the reported spectrum of pembrolizumab-associated RP by documenting an airway-predominant, treatment refractory course with serial immune phenotyping and long-term post-stenting follow-up.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedPolychondritis, RelapsingCD8-Positive T-LymphocytesLymphocyte ActivationStentsImmune Checkpoint InhibitorsAntineoplastic Agents, ImmunologicalHumansMaleAgedAdenocarcinoma of LungLung Neoplasms

Stichwörter der Autor:innen

CD8+ T-cell activationbronchial stentingimmune checkpoint inhibitorimmune-related adverse eventrelapsing polychondritis

Substanzen

Antibodies, Monoclonal, HumanizedpembrolizumabImmune Checkpoint InhibitorsAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Respiratory and Critical Care Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Xia, C., Chen, J., Fang, X., Deng, C., Zhu, X., Ye, S., & Wang, R. (2026). Case Report: Pembrolizumab-associated airway-predominant relapsing polychondritis with longitudinal CD8+ T-cell activation and bronchial stenting. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1999620

Vancouver

Xia C, Chen J, Fang X, Deng C, Zhu X, Ye S, et al. Case Report: Pembrolizumab-associated airway-predominant relapsing polychondritis with longitudinal CD8+ T-cell activation and bronchial stenting. Frontiers in Immunology. 2026. doi:10.3389/fimmu.2026.1999620

BibTeX
@article{Xia2026,
  author = {Xia, Can and Chen, Jie and Fang, Xia and Deng, Changwen and Zhu, Xiaoping and Ye, Shuang and Wang, Runci},
  title = {Case Report: Pembrolizumab-associated airway-predominant relapsing polychondritis with longitudinal CD8+ T-cell activation and bronchial stenting},
  journal = {Frontiers in Immunology},
  year = {2026},
  doi = {10.3389/fimmu.2026.1999620}
}
Kostenlos starten →